Medicus Pharma sets 50-to-1 reverse split effective Oct 12 to regain Nasdaq minimum bid price compliance

Medicus Pharma Ltd.

Fifty-to-one share consolidation effective October 12, 2026: every 50 common shares automatically exchanged for one new share; ticker remains MDCX.
Board approved the ratio under shareholder authorization granted at the June 3, 2026 Annual General and Special Meeting for a consolidation of up to fifty-to-one.
Common shares expected to trade on a consolidated basis on the Nasdaq Capital Market at the open on October 12, 2026, under new CUSIP 58471K301 and ISIN CA58471K3010.
No fractional shares will be issued; holders of non-evenly-divisible positions are rounded down to the next whole share with cash paid in lieu.
Exercise prices and share counts of outstanding equity awards, convertible securities and warrants, plus shares reserved under equity incentive plans, will be adjusted proportionately.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.